Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

Poseida Therapeutics, a US-based gene therapy developer backed by pharmaceutical firm Novartis, completed a $110m series D round on Thursday led by funds advised by investment and financial services group Fidelity. Adage Capital Management, Schonfeld Strategic Advisors and unnamed existing shareholders also took part in the round, which closed just two days after Poseida filed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.